EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer

Moonsik Kim, Ji Yun Jeong iD, An Na Seo iD

Diagnostics · 28.08.2023 · 13 (17) · 2782

DOI: 10.3390/diagnostics13172782 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 28.08.2023. Verfasst von Moonsik Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Kyungpook National University, 136-gil 90, Chilgokjungang-daero, Buk-gu, Daegu 41405, Republic of Korea. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Research Institute grant, Kyungpook National University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in diagnostic imaging, surgical techniques, and systemic therapy, gastric cancer (GC) is the third leading cause of cancer-related death worldwide. Unfortunately, molecular heterogeneity and, consequently, acquired resistance in GC are the major causes of failure in the development of biomarker-guided targeted therapies. However, by showing promising survival benefits in some studies, the recent emergence of immunotherapy in GC has had a significant impact on treatment-selectable procedures. Immune checkpoint inhibitors (ICIs), widely indicated in the treatment of several malignancies, target inhibitory receptors on T lymphocytes, including the programmed cell death protein (PD-1)/programmed death-ligand 1 (PD-L1) axis and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and release effector T-cells from negative feedback signals. In this article, we review currently available predictive biomarkers (including PD-L1, microsatellite instability, Epstein–Barr virus, and tumor mutational burden) that affect the ICI treatment response, focusing on PD-L1 expression. We further briefly describe other potential biomarkers or mechanisms for predicting the response to ICIs in GC. This review may facilitate the expansion of the understanding of biomarkers for predicting the response to ICIs and help select the appropriate therapeutic approaches for patients with GC.

Schlagwörter

Stichwörter der Autor:innen

biomarkergastric cancerimmunotherapymolecular pathologyprogrammed cell death-ligand 1

Autor:innen und Institutionen

  • Department of Pathology, School of Medicine, Kyungpook National University, 136-gil 90, Chilgokjungang-daero, Buk-gu, Daegu 41405, Republic of Korea.
  • Department of Pathology, Kyungpook National University Chilgok Hospital, 807 Hogukno, Buk-gu, Daegu 41404, Republic of Korea.

ORCID-Profile: Ji Yun Jeong, An Na Seo

Förderung

  • Biomedical Research Institute grant, Kyungpook National University Hospital

Zitieren

APA

Kim, M., Jeong, J. Y., & Seo, A. N. (2023). Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer. Diagnostics, 13(17), 2782. https://doi.org/10.3390/diagnostics13172782

Vancouver

Kim M, Jeong JY, Seo AN. Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer. Diagnostics. 2023;13(17):2782. doi:10.3390/diagnostics13172782

BibTeX
@article{Kim2023,
  author = {Kim, Moonsik and Jeong, Ji Yun and Seo, An Na},
  title = {Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer},
  journal = {Diagnostics},
  year = {2023},
  volume = {13},
  number = {17},
  pages = {2782},
  doi = {10.3390/diagnostics13172782}
}
Kostenlos starten →